| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.7 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.023 | 0.7 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |